Paul Schloesser

Grit Biotech­nol­o­gy said Fri­day that it closed a Se­ries B, rais­ing more than $60 mil­lion from sev­er­al Chi­nese in­vestors. The fi­nanc­ing came from sev­er­al new

Verge Ge­nomics has se­cured its largest deal yet, link­ing up with As­traZeneca’s rare dis­ease di­vi­sion Alex­ion in a deal worth up to $882 mil­lion. The

Al­ny­lam’s zilebe­sir­an met the pri­ma­ry end­point and cer­tain sec­ondary end­points in a Phase II dose-rang­ing tri­al in a read­out that ar­rived less than six weeks

CymaBay Ther­a­peu­tics’ lead can­di­date met the pri­ma­ry end­point and key sec­ondary end­points in a Phase III tri­al for a liv­er dis­ease, set­ting the stage for

The US Dis­trict Court for the South­ern Dis­trict of Cal­i­for­nia ruled last week in fa­vor of San Diego-based Shore­line Bio­sciences, re­ject­ing ar­gu­ments from Fate Ther­a­peu­tics

Apol­lo Ther­a­peu­tics is reel­ing in a $226.5 mil­lion Se­ries C round, the biotech said Wednes­day. The fi­nanc­ing is two-pronged: It aims to ad­vance Apol­lo’s clin­i­cal

US pol­i­cy­mak­ers and pay­ers should con­sid­er in­di­ca­tion-based pric­ing in a bid to cut down on high­er can­cer drug costs in the US, ac­cord­ing to re­search

CCM Bio­sciences launched out of stealth Tues­day, tout­ing ten drug pro­grams and more than $25 mil­lion raised from Se­ries A1 and A2 rounds. CCM has

Bris­tol My­ers Squibb has scored an­oth­er win for its ane­mia drug Re­blozyl, re­veal­ing Mon­day evening the FDA grant­ed the drug its third in­di­ca­tion. The FDA

Gink­go Bioworks is col­lab­o­rat­ing with Google Cloud on a five-year AI part­ner­ship, the biotech an­nounced Tues­day. The part­ner­ship will be cen­tered around Gink­go work­ing on